LENZ THERAPEUTICS INC (LENZ)

Wednesday 5/15 Insider Buying Report: AKAM, LENZ

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in...

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical...

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress